End-to-End Cell Therapy Automation

본 발명은 완전 밀폐식 세포 공학 시스템을 이용하여 키메라 항원 수용체 T (CAR T) 세포를 포함한 유전적으로 변형된 면역 세포의 자동화된 제조방법을 제공한다. The present disclosure provides an automated method of producing genetically modified immune cells, including chimeric antigen receptor T (CAR T) cells, utilizing a fully-enclosed cell engineering system....

Full description

Saved in:
Bibliographic Details
Main Authors TRAINOR NUALA, PURPURA KELLY, SMITH TIMOTHY, ABRAHAM EYTAN, MCAFEE ERIKA, GLEISSNER TIMO, O'CONNOR JOSEPH, SHI YALING, BANDAPALLE SAMATHA, SIEHOFF ANN
Format Patent
LanguageEnglish
Korean
Published 23.06.2023
Subjects
APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY
BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS THEREOF
CULTURE MEDIA
ENZYMOLOGY
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
SPIRITS
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:본 발명은 완전 밀폐식 세포 공학 시스템을 이용하여 키메라 항원 수용체 T (CAR T) 세포를 포함한 유전적으로 변형된 면역 세포의 자동화된 제조방법을 제공한다. The present disclosure provides an automated method of producing genetically modified immune cells, including chimeric antigen receptor T (CAR T) cells, utilizing a fully-enclosed cell engineering system.
Bibliography:Application Number: KR20237020204